Forecast Insight: Top 20 Cancer Therapy Brands Targeted therapies will drive market growth in the wake of the cytotoxic and antihormonal patent cliff

Published Date: September 2009 Published By: Datamonitor Page Count: 108 Order Code: R313-54629 $15,200.00   Online Download $38,000.00   Global Site License   Questions About This Report E-mail a Colleague Printable Page Fax Your Order Description Table of Contents Similar Products Introduction The cancer therapies market offers a high level of commercial reward to a handful of companies including Roche, Sanofi-Aventis, AstraZeneca, Novartis and Eli Lilly. Cancer therapy sales totaled over $38 billion in the seven major pharmaceutical markets in 2008, growing at a CAGR of 17.4% between 2005 and 2008. Scope Forecast sales of the leading 20 cancer therapy brands in each of the seven major markets over the period 2008 to 2018Analysis and segmentation of the total cancer therapies market at various levels including drug class, country and brandComprehensive profiles and analysis for the key brands, including approval dates, patent expiries and all key events likely to impact salesSnapshot of the cancer therapies market in the rest of the worldHighlights Datamonitor forecasts the cancer therapies market to reach sales of $70.4 billion by 2018. Sales growth over the forecast period will slow as some of the highest selling brands undergo patent expiry and several other brands will approach market saturation. Molecular targeted therapies will continue to drive most of the growth of the cancer therapies market over the forecast period 20082018. This reflects this class's potential for increased uptake in existing indications, further indication expansions, relatively low incursion from generics and the modest impact of biosimilar market entrants. Roche's monoclonal antibody franchise dominated the cancer therapies market in 2008 and will continue to do so through to 2018. Avastin was the top selling cancer therapy brand in 2008 and will remain the leading brand through to 2018. Expansion across a number of new tumor types and increasing uptake in new territories will drive this growth. Reasons to Purchase Quantify the performance of each of leading 20 cancer therapies in the seven major markets over the period 2008 to 2018Assess the changing key opportunities and threats both for currently marketed and pipeline cancer therapy brandsIdentify the leading brands in this market over the next 10 years and understand the key factors driving their success Please note: this is delivered as a Zip file. Similar Products • Snapshots US Pharmaceuticals 2009 Published Nov 2009 by Snapdata International Group • Pharmaceutical Industry in the United States - Porter’s Five Forces Strategy Analysis Published Nov 2009 by Aruvian's R'search • Pharmaceutical Industry in Mexico Published Nov 2009 by Aruvian's R'search • Pharmaceuticals Industry Report Published Nov 2009 by Plimsoll Publishing Ltd. • Antipsychotics Market Forecast Published Oct 2009 by Datamonitor • Commercial Insight: Antidiabetics in Australia - Reimbursement status shapes novel classes Published Oct 2009 by Datamonitor • Prescription Drug Wholesaling in the US - Industry Risk Rating Report Published Oct 2009 by IBISWorld • Antidepressants Market Forecast Published Oct 2009 by Datamonitor • Snapshots Bulgaria Pharmaceuticals 2009 Published Oct 2009 by Snapdata International Group • Snapshots Australia Pharmaceuticals 2009 Published Oct 2009 by Snapdata International Group